Evidence map›Paper›PMID 42583451›Full record

ArticleJournal of thoracic disease2026

Efficacy and safety of high-dose prednisone for patients with advanced thymoma: a retrospective study.

Ning Xu, Xuefei Zhang, Ying Yang, Yu Yang, Changlu Wang, Zhiqiang Gao, Feng Pan, Yan Shen, Lei Zhu, Zhitao Gu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ning Xu *Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xuefei Zhang *Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ying Yang *Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu YangDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Changlu WangDepartment of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhiqiang GaoDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Feng PanDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yan ShenDepartment of Radiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lei ZhuDepartment of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhitao GuDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Teng MaoDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chemotherapeutic treatments for advanced thymoma have limited efficacy and a high rate of adverse events, while it has been reported that glucocorticoids (GCs) may be effective in this context. This study aimed to retrospectively analyze the efficacy and safety of high-dose prednisone for patients with advanced thymoma in a single center in order to determine the optimal application scenarios for GCs in the treatment of these patients. Methods: Patients with previously treated advanced tumor-node-metastasis (TNM) (8 Results: A total of 26 patients were included, with 15 (57.7%) having primary stage III-IV diseases and 11 (42.3%) having pleural recurrent stage IV diseases. The objective response rate (ORR) of prednisone was 57.7% (15/26), with 2 cases of complete response (CR) and 13 cases of partial response (PR). Ten (38.5%) patients had stable disease (SD), and 1 (3.8%) had progressive disease (PD). All patients had type B thymomas. The ORR was relatively higher in type B1 tumors than in the other subtypes (71.4% Conclusions: High-dose prednisone is effective and safe for the treatment of advanced thymoma. It might be particularly effective in induction therapy before surgery or in creating the opportunity for radiotherapy. The long-term administration of prednisone should be selected with careful consideration of its potential side effects.

Indexed as

advancedhigh dosePrednisonethymoma

Identifiers

PMID42583451
PMCPMC13460208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.